← Oncology Approval Tracker

FDA DECISION ·

Yartemlea

narsoplimab-wuug · Omeros

FDA approvalNew therapyTransplant-associated thrombotic microangiopathy
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults and children age 2 years or older with hematopoietic stem cell transplant-associated thrombotic microangiopathy.

LAMPGEN ANALYSIS

Why it matters

This MASP-2 inhibitor is the first approved treatment for the potentially life-threatening post-transplant complication.

What research teams should watch

Plan rapid transplant-team recognition of TA-TMA and track blood markers, transfusion needs, organ function, and infections.

PRIMARY RECORDS

Sources